A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy

Satoh, Minoru; Tanaka, Shin; Ceribelli, Angela; Calise, S. John; Chan, Edward K. L.

doi:10.1007/s12016-015-8510-y

Cited by 326 publications

(282 citation statements)

References 126 publications

Supporting

Mentioning

252

Contrasting

Unclassified

Order By: Relevance

“…Because of their strong associations with a pattern of clinical features, such as myopathy, skin lesions, and ILD, these novel autoantibodies are useful biomarkers for classifying disease subgroups, predicting future organ involvement, and forecasting the prognosis of patients with PM/DM [114,[128][129][130][131]. The autoantibodies are detectable in PM/DM; both MSA and MAA are listed and summarized in Table 4 [102].…”

Section: Myositis-specific Autoantibodies and Myositis-associated Autmentioning

confidence: 99%

Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight

Ishii¹

2017

Contemporary Topics of Pneumonia

View full text Add to dashboard Cite

Interstitial pneumonia (IP) refers to involvement of the lung parenchyma by varying degrees of inflammation and fibrosis, in contrast to airspace disease typically seen in bacterial pneumonia. IP lies in the center of a heterogenous group of diffuse interstitial lung diseases (ILDs), either idiopathic or linked to underlying disorders. One of the major categories of disorders frequently associated with IP is a connective tissue disease (CTD), in which autoimmunemediated tissue injury leads to multiple organ impairment. Today, IP represents the most critical pulmonary complication in CTD, resulting in significant morbidity and mortality.Despite growing understanding of the pathology of IPs, as well as the accumulating knowledge from both basic and clinical studies of CTDs, the pathogenesis of CTD-associated IP remains unclear. This chapter will provide an overview of the general understanding of ILD and illustrate the current state of knowledge on IP associated with CTD, in order to fully comprehend the entirety of its complex pictures. Moreover, we will propose a new insight into the immune pathogenesis of CTD-IP by presenting evidence which robustly indicates that T cells trigger initial development of IP in polymyositis/dermatomyositis, suggesting potential approaches for controlling such particular T cells in therapeutic interventions for IP.

show abstract

Section: Myositis-specific Autoantibodies and Myositis-associated Autmentioning

confidence: 99%

Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight

Ishii¹

2017

Contemporary Topics of Pneumonia

View full text Add to dashboard Cite

show abstract

“…Overlap with other rheumatic diseases may be present, for example with systemic lupus erythematosus or systemic sclerosis (10). Several immunological findings are characteristic of PM: autoantibodies (including antinuclear antibodies) in up to 80% of patients; myositis-specific autoantibodies in at least 30-40% of patients (antisynthetase antibodies and antibodies to signal recognition particle -SRP); and myositis-associated autoantibodies (antiRo, anti-La, anti-Sm, or anti-RNP antibodies) especially in patients with overlap syndromes (11).…”

Section: Case Reportmentioning

confidence: 99%

Acute heart failure and rhabdomyolysis: a clue for the diagnosis of polymyositis with cardiac involvement

et al. 2017

View full text Add to dashboard Cite

SUMMARYPolymyositis is an idiopathic inflammatory myopathy, characterized by proximal muscle weakness and sometimes extramuscular manifestations. We report the case of a 51-year-old male, with history of complete heart block, which required pacemaker implantation, and subsequently heart failure, presenting to the emergency department with worsening of dyspnea and peripheral edema. He was admitted to the Internal Medicine ward with acute heart failure and started on diuretic therapy. During hospitalization, he was discovered to have marked rhabdomyolysis. Examination revealed proximal symmetrical muscle weakness and arthralgia. The immunological study, electromyography and muscle biopsy confirmed polymyositis. The patient was started on prednisolone with clinical improvement and resolution of rhabdomyolysis. The presence of conduction defect, ventricular dysfunction, mitral valve regurgitation, segmental hypokinesia (myocardial scintigraphy without perfusion defects) and pulmonary hypertension, as well as elevated troponin with improvement after specific therapy, points to cardiac involvement. Polymyositis is a rare entity, with an insidious evolution and a myriad of extramuscular features that can mimic other conditions. In particular, cardiac involvement may be the first and only recognized manifestation. The key point for the diagnosis is to contemplate the possibility of polymyositis.

show abstract

“…Eight types of anti-ARS antibodies have been thus far identified. 7 They have been found to be prevalent in arthritis and interstitial lung disease (ILD), skin lesions, and idiopathic interstitial pneumonia. [8][9][10][11] Several studies on anti-ARS antibodies in PM/DM patients have been conducted and their correlation with certain clinical presentations has been shown.…”

mentioning

confidence: 99%

“…[8][9][10][11] Several studies on anti-ARS antibodies in PM/DM patients have been conducted and their correlation with certain clinical presentations has been shown. 7,12 However, limited information is available on the incidence of anti-ARS antibodies in other connective tissue disorders. Therefore, in this study, we aimed to analyze the distribution and clinicopathological characteristics of anti-ARS antibodies in rheumatoid arthritis (RA) patients.…”

mentioning

confidence: 99%

The Association of Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibodies in Patients With Rheumatoid Arthritis and Interstitial Lung Disease

et al. 2018

View full text Add to dashboard Cite

Objectives:This study aims to analyze the distribution and clinicopathological characteristics of anti-aminoacyl-transfer ribonucleic acid (tRNA) synthetase (ARS) antibodies in rheumatoid arthritis patients. Patients and methods:We retrospectively studied the anti-ARS antibody levels in 228 RA patients' (44 males, 184 females; mean age 62.9±14.0 years; range 23 to 88 years) sera from their medical charts. We determined the association with anti-cyclic citrullinated peptide antibody levels, interstitial lung disease (ILD), rheumatoid factor, and methotrexate or biological disease modifying antirheumatic drug treatments. Results: Anti-ARS antibodies were detected in 14 RA patients (6.1%). ILD complications were significantly higher among anti-ARS antibody-positive patients (57.1% vs 22.4%, p<0.05). Levels of anti-threonyl-tRNA-synthetase (anti-PL-7) and anti-alanyl-tRNA-synthetase (anti-PL-12), two anti-ARS antibodies, were higher in RA patients with concurrent ILD (both p<0.05). Myositis and ILD worsening were not observed in three anti-ARS antibodypositive patients despite biological disease modifying antirheumatic drug administration. There was no difference in anti-cyclic citrullinated peptide and rheumatoid factor specificities between patients with or without ARS antibodies. Conclusion: Anti-ARS antibodies were detected in RA patients, with higher prevalence in patients with concurrent ILD. RA patients, specifically those with ILD complications, should be tested for anti-ARS antibodies.

show abstract

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy

Cited by 326 publications

References 126 publications

Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight

Interstitial Pneumonia Associated with Connective Tissue Disease: An Overview and an Insight

Acute heart failure and rhabdomyolysis: a clue for the diagnosis of polymyositis with cardiac involvement

The Association of Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibodies in Patients With Rheumatoid Arthritis and Interstitial Lung Disease

Contact Info

Product

Resources

About